129 related articles for article (PubMed ID: 18184406)
1. The effect of antifungal agents and human monocytes on in vitro galactomannan release by Aspergillus spp. in liquid culture medium.
Winn RM; Warris A; Gaustad P; Abrahamsen TG
APMIS; 2007 Dec; 115(12):1364-9. PubMed ID: 18184406
[TBL] [Abstract][Full Text] [Related]
2. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
4. Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assay.
Balajee SA; Imhof A; Gribskov JL; Marr KA
J Antimicrob Chemother; 2005 Jan; 55(1):102-5. PubMed ID: 15546970
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B.
Moore CB; Walls CM; Denning DW
Antimicrob Agents Chemother; 2001 Jun; 45(6):1882-5. PubMed ID: 11353643
[TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast One.
Carrillo-Muñoz AJ; Quindós G; Ruesga M; del Valle O; Pemán J; Cantón E; Hernández-Molina JM; Santos P
Mycoses; 2006 Jul; 49(4):293-7. PubMed ID: 16784443
[TBL] [Abstract][Full Text] [Related]
7. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
8. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
Espinel-Ingroff A; Johnson E; Hockey H; Troke P
J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
Li L; Wang Z; Li R; Luo S; Sun X
Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
[TBL] [Abstract][Full Text] [Related]
10. Rapid method for testing the susceptibility of Aspergillus fumigatus to amphotericin B, itraconazole, voriconazole and posaconazole by assessment of oxygen consumption.
Araujo R; Coutinho I; Espinel-Ingroff A
J Antimicrob Chemother; 2008 Dec; 62(6):1277-80. PubMed ID: 18824456
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.
Hope WW; Kruhlak MJ; Lyman CA; Petraitiene R; Petraitis V; Francesconi A; Kasai M; Mickiene D; Sein T; Peter J; Kelaher AM; Hughes JE; Cotton MP; Cotten CJ; Bacher J; Tripathi S; Bermudez L; Maugel TK; Zerfas PM; Wingard JR; Drusano GL; Walsh TJ
J Infect Dis; 2007 Feb; 195(3):455-66. PubMed ID: 17205486
[TBL] [Abstract][Full Text] [Related]
12. [In vitro sensitivity of Histoplasma capsulatum var. capsulatum to amphotericin B, ketoconazole, itroconazole and fluconazole].
Andreu CM; León AM; Medina YE; Machín GM; Lancha MR; Zaragozí MT
Rev Cubana Med Trop; 2003; 55(2):76-82. PubMed ID: 15849960
[TBL] [Abstract][Full Text] [Related]
13. Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus.
Dotis J; Simitsopoulou M; Dalakiouridou M; Konstantinou T; Taparkou A; Kanakoudi-Tsakalidou F; Walsh TJ; Roilides E
Antimicrob Agents Chemother; 2006 Mar; 50(3):868-73. PubMed ID: 16495244
[TBL] [Abstract][Full Text] [Related]
14. The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions.
Meletiadis J; te Dorsthorst DT; Verweij PE
Int J Antimicrob Agents; 2006 Nov; 28(5):439-49. PubMed ID: 17055706
[TBL] [Abstract][Full Text] [Related]
15. Correlation between CLSI, EUCAST and Etest methodologies for amphotericin B and fluconazole antifungal susceptibility testing of Candida spp. clinical isolates.
Claudino AL; Peixoto RF; Melhem MS; Szeszs MW; Lyon JP; Chavasco JK; Franco MC
Pharmazie; 2008 Apr; 63(4):286-9. PubMed ID: 18468388
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.
Nagasaki Y; Eriguchi Y; Uchida Y; Miyake N; Maehara Y; Kadowaki M; Harada M; Akashi K; Shimono N
J Antimicrob Chemother; 2009 Aug; 64(2):379-82. PubMed ID: 19465436
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.
Kovanda LL; Desai AV; Hope WW
J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):143-151. PubMed ID: 28181136
[TBL] [Abstract][Full Text] [Related]
18. Aspergillus vertebral osteomyelitis in a child with a primary monocyte killing defect: response to GM-CSF therapy.
Abu Jawdeh L; Haidar R; Bitar F; Mroueh S; Akel S; Nuwayri-Salti N; Dbaibo GS
J Infect; 2000 Jul; 41(1):97-100. PubMed ID: 11041713
[TBL] [Abstract][Full Text] [Related]
19. Mycological and serological study of pulmonary aspergillosis in central India.
Kurhade AM; Deshmukh JM; Fule RP; Chande C; Akulwar S
Indian J Med Microbiol; 2002; 20(3):141-4. PubMed ID: 17657053
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive interferon-γ immunotherapy in a pediatric case of Aspergillus terreus infection.
Assendorp EL; Gresnigt MS; Sprenkeler EGG; Meis JF; Dors N; van der Linden JWM; Henriet SSV
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1915-1922. PubMed ID: 30027379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
